What You Should Know:
– Courier Health, a technology company transforming patient experiences in the life sciences industry raises $16.5M in Series A funding led by Norwest Venture Partners with participation from existing investor Work-Bench.
– The investment fuels Courier Health’s mission to provide biopharma companies with the tools to manage and personalize the patient journey for life-altering therapies.
Addressing the Rise of Specialty Medicines
The landscape of medicine is rapidly evolving. Specialty medications, often requiring complex treatment plans and ongoing support, now account for a staggering 93% of all drug approvals and dominate R&D pipelines. While biopharma companies are building internal teams to address patient access, affordability, and adherence needs, they struggle with the technological infrastructure to efficiently coordinate care across various stakeholders.
Courier Health: A Purpose-Built Solution
Courier Health bridges this gap by offering the only patient-based CRM platform specifically designed for the biopharma industry. This comprehensive solution empowers biopharma companies’ field access, patient services, and marketing teams with:
- Complete Visibility: Gain a clear picture of the entire patient journey, from initial contact to ongoing treatment.
- Centralized Management: Manage patient and provider data efficiently from a single platform.
- Omnichannel Automation: Automate workflows across various communication channels, streamlining care coordination.
- Advanced Analytics: Leverage data-driven insights to optimize patient engagement and improve treatment outcomes.
Cost-Effective and Results-Driven
Unlike expensive custom-built software, Courier Health’s platform offers a cost-effective, user-friendly solution. Biopharmaceutical companies adopting Courier Health have reported significant improvements, including double-digit increases in patient starts, time-to-start treatment, and adherence to life-saving therapies.
“The number of specialty medicines has exploded over the last decade, forcing the evolution of commercial models to focus on the patient experience,” said Danny Sigurdson, founder and CEO of Courier Health. “Unfortunately, the industry average remains that 60% to 70% of patients who are prescribed a specialty medicine either never start or discontinue within the first few months. We are thrilled to work with Norwest Venture Partners to advance our product innovation and add best-in-class talent to help more patients start and stay on these critically important medicines.”
